Skip to Content

Esperoct Approval History

FDA Approved: Yes (First approved February 19, 2019)
Brand name: Esperoct
Generic name: turoctocog alfa pegol
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Hemophilia A

Esperoct (turoctocog alfa pegol, N8-GP) is an extended half-life factor VIII molecule for the treatment of adults and children with hemophilia A.

Development History and FDA Approval Process for Esperoct

Feb 19, 2019Approval FDA Approves Esperoct (turoctocog alfa pegol, N8-GP) for Hemophilia A

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.